December 2002
Volume 43, Issue 13
ARVO Annual Meeting Abstract  |   December 2002
Connective Tissue Growth Factor Regulates TGF-ß1-Mediated Matrix Contraction by Fibroblasts
Author Affiliations & Notes
  • JT Daniels
    Wound Healing Research Unit Institute of Ophthalmology London United Kingdom
  • GS Schultz
    Institute of Wound Research University of Florida Gainsville FL
  • GR Grotendorst
    Dept of Anatomy and Cell Biology University of Miami Miami FL
  • NM Dean
    ISIS Pharmaceuticals Carlsbad CA
  • PT Khaw
    Wound Healing Research Unit Institute of Ophthalmology London United Kingdom
  • Footnotes
    Commercial Relationships   J.T. Daniels, None; G.S. Schultz, None; G.R. Grotendorst, None; N.M. Dean, None; P.T. Khaw, None. Grant Identification: Royal National Institute for the Blind, UK
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 858. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      JT Daniels, GS Schultz, GR Grotendorst, NM Dean, PT Khaw; Connective Tissue Growth Factor Regulates TGF-ß1-Mediated Matrix Contraction by Fibroblasts . Invest. Ophthalmol. Vis. Sci. 2002;43(13):858.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: To investigate whether CTGF regulates TGF-ß1-mediated matrix contraction by fibroblasts and to determine if matrix metalloproteinases are involved. Methods: Fibroblasts explanted from human corneal stroma were cultured in DMEM plus 10% serum. Serum-free fibroblast-populated type I collagen gels were fed with test media. The test groups were: TGF-ß1 or CTGF (2.5 - 25 ng/ml), TGF-ß1 (25 ng/ml) plus concentrations of antisense and scrambled oligonucleotides to CTGF or CTGF neutralising antibody (10 µg/ml), TGF-ß1 or CTGF (25 ng/ml) plus concentrations of the MMP inhibitor, Galardin (1-100 µM). Matrix contraction was measured using digital images and analysis software (UTHSCSA Image Tool). MMP activity in conditioned medium from contracting gels was analysed by zymography. Cell viability was assessed with the reagent WST-1. Results: Fibroblast-mediated matrix contraction increased with concentrations of TGF-ß1 and CTGF (maximal contraction 81% and 79% respectively; p<0.001). TGF-ß1-mediated contraction was reduced approximately 46% by anti-sense oligonucleotide targeting CTGF and 26% by CTGF neutralising antibody (p<0.001). Controls did not inhibit contraction. MMP-2 and MMP-9 were produced during contraction, and inhibition of MMPs reduced matrix contraction induced by TGF-ß1 and CTGF (p<0.001). None of the treatments were toxic. Conclusions: Addition of TGF-ß1 or CTGF stimulated fibroblast-mediated matrix contraction dose dependently. Inhibition of CTGF synthesis by antisense oligonucleotide or CTGF neutralisation by a specific antibody significantly reduced TGF-ß1-mediated matrix contraction by fibroblasts, indicating that CTGF mediates many effects of TGF-ß1 on matrix contraction. Whilst MMPs were found to be involved in fibroblast-mediated matrix contraction, a direct relationship between CTGF and MMP production is not yet clear. These data suggest a novel CTGF-mediated regulatory mechanism for TGF-ß1 during wound healing and indicate that CTGF may be a potential target for anti-scarring therapy.

Keywords: 370 cornea: basic science • 423 growth factors/growth factor receptors • 631 wound healing 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.